Which non-opioid analgesic is most associated with liver toxicity and what monitoring is prudent?

• A. Acetaminophen; monitor liver enzymes with chronic high-dose use.
• B. Ibuprofen; monitor liver enzymes.
• C. Gabapentin; monitor liver enzymes.
• D. Acetaminophen; monitor liver enzymes with chronic high-dose use.

Answer: (D)

Acetaminophen is the non-opioid analgesic most associated with liver toxicity, especially when used chronically at high doses. The liver injury risk comes from a metabolite (NAPQI) that forms when acetaminophen is processed in the liver; when dose is too high or glutathione stores are depleted (as with chronic high-dose use, poor nutrition, or alcohol use), NAPQI can accumulate and damage hepatocytes. That’s why monitoring liver function is prudent for patients on chronic high-dose therapy—baseline liver enzymes plus periodic tests (ALT/AST, with bilirubin as needed) help detect early signs of injury before symptoms appear. Reinforce safe dosing (usually not exceeding about 4 g per day for adults, with adjustments for liver disease or alcohol use) and avoid multiple acetaminophen-containing products to prevent inadvertent overdose. In overdose, prompt treatment with N-acetylcysteine can prevent serious liver damage. The other choices aren’t as strongly linked to liver toxicity, since ibuprofen raises GI/renal risks and gabapentin isn’t typically associated with significant liver enzyme elevations, making chronic liver monitoring less routinely indicated for them.